Lucie Blais1,2,3, Fatima-Zohra Kettani4,5, Amélie Forget4,5, Marie-France Beauchesne4,6,7,8, Catherine Lemière4,5, Francine M Ducharme9,10. 1. Faculté de Pharmacie, Université de Montréal, Montréal, QC, Canada. lucie.blais@umontreal.ca. 2. Hôpital du Sacré-Cœur de Montréal, Montréal, QC, Canada. lucie.blais@umontreal.ca. 3. Endowment Pharmaceutical Chair AstraZeneca in Respiratory Health, Montréal, QC, Canada. lucie.blais@umontreal.ca. 4. Faculté de Pharmacie, Université de Montréal, Montréal, QC, Canada. 5. Hôpital du Sacré-Cœur de Montréal, Montréal, QC, Canada. 6. Endowment Pharmaceutical Chair AstraZeneca in Respiratory Health, Montréal, QC, Canada. 7. Pharmacy Department, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada. 8. Centre de Recherche Clinique, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada. 9. Clinical Research and Knowledge Transfer Unit on Childhood Asthma, Research Centre, CHU Sainte-Justine, Montreal, Canada. 10. Department of Pediatrics, University of Montréal, Montréal, QC, Canada.
Abstract
PURPOSE: There are very few studies on primary adherence (i.e., first filling of a prescription) to inhaled corticosteroids (ICS) in asthma patients; two have involved children. Moreover, adherence can be overestimated when considering only secondary adherence (i.e., following the medication recommendations for a defined period) and ignoring primary adherence. We aimed thus to evaluate the real-world primary and secondary adherence to ICS and to develop an integrated primary and secondary adherence (IPSA) measure. METHODS: From two clinical databases of pediatric and adult asthma patients, we included 198 children and 206 adults with one ICS prescription recorded in their medical chart between 2010 and 2012 and follow-up data for ≥12 months. Adherence was estimated from written prescriptions and prescription claims data. Primary adherence was defined as filling the ICS prescription at a pharmacy within 12 months. Secondary adherence was defined as the proportion of days covered (PDC) in subjects who filled their prescription at least once. The IPSA was based on the PDC with a correction factor for primary adherence. RESULTS: Primary adherence to ICS at 12 months was 89.4 % in children and 69.4 % in adults. Secondary adherence at 12 months in children was 33.9 %, and the IPSA was 30.3 %. These values were 52.8 and 36.6 %, respectively, in adults. CONCLUSIONS: Primary adherence to ICS is low in adults and secondary adherence is poor in children and adults. Using the PDC as a unique measure of adherence led to significant overestimation in adults; IPSA leads to more valid estimates of adherence to ICS.
PURPOSE: There are very few studies on primary adherence (i.e., first filling of a prescription) to inhaled corticosteroids (ICS) in asthmapatients; two have involved children. Moreover, adherence can be overestimated when considering only secondary adherence (i.e., following the medication recommendations for a defined period) and ignoring primary adherence. We aimed thus to evaluate the real-world primary and secondary adherence to ICS and to develop an integrated primary and secondary adherence (IPSA) measure. METHODS: From two clinical databases of pediatric and adult asthmapatients, we included 198 children and 206 adults with one ICS prescription recorded in their medical chart between 2010 and 2012 and follow-up data for ≥12 months. Adherence was estimated from written prescriptions and prescription claims data. Primary adherence was defined as filling the ICS prescription at a pharmacy within 12 months. Secondary adherence was defined as the proportion of days covered (PDC) in subjects who filled their prescription at least once. The IPSA was based on the PDC with a correction factor for primary adherence. RESULTS: Primary adherence to ICS at 12 months was 89.4 % in children and 69.4 % in adults. Secondary adherence at 12 months in children was 33.9 %, and the IPSA was 30.3 %. These values were 52.8 and 36.6 %, respectively, in adults. CONCLUSIONS: Primary adherence to ICS is low in adults and secondary adherence is poor in children and adults. Using the PDC as a unique measure of adherence led to significant overestimation in adults; IPSA leads to more valid estimates of adherence to ICS.
Authors: Francine M Ducharme; Francisco J D Noya; Felicia C Allen-Ramey; Eric M Maiese; Joanie Gingras; Lucie Blais Journal: Curr Med Res Opin Date: 2011-12-16 Impact factor: 2.580
Authors: Gregory Moullec; Gabrielle Gour-Provencal; Simon L Bacon; Tavis S Campbell; Kim L Lavoie Journal: Respir Med Date: 2012-07-05 Impact factor: 3.415
Authors: Michael A Fischer; Niteesh K Choudhry; Gregory Brill; Jerry Avorn; Sebastian Schneeweiss; David Hutchins; Joshua N Liberman; Troyen A Brennan; William H Shrank Journal: Am J Med Date: 2011-11 Impact factor: 4.965
Authors: Marsha A Raebel; Julie Schmittdiel; Andrew J Karter; Jennifer L Konieczny; John F Steiner Journal: Med Care Date: 2013-08 Impact factor: 2.983
Authors: Kimberly J Arcoleo; Colleen McGovern; Karenjot Kaur; Jill S Halterman; Jennifer Mammen; Hugh Crean; Deepa Rastogi; Jonathan M Feldman Journal: Ann Am Thorac Soc Date: 2019-06
Authors: Omer Kalayci; Hanan Abdelateef; César Fireth Pozo Beltrán; Zeinab A El-Sayed; René Maximiliano Gómez; Elham Hossny; Mário Morais-Almeida; Antonio Nieto; Wanda Phipatanakul; Paulo Pitrez; Gary Wk Wong; Paraskevi Xepapadaki; Nikolaos G Papadopoulos Journal: World Allergy Organ J Date: 2019-10-03 Impact factor: 4.084
Authors: Holly Tibble; James Lay-Flurrie; Aziz Sheikh; Rob Horne; Mehrdad A Mizani; Athanasios Tsanas Journal: BMC Med Res Methodol Date: 2020-12-10 Impact factor: 4.615